Substance Use Disorders (SUD)MDMAPsilocybin

Experienced drug users assess the relative harms and benefits of drugs: a web-based survey

This survey study (n=93) investigated the subjective harms and benefits of eleven drugs as reported by experienced drug users. Alcohol and tobacco were ranked as the most harmful, MDMA, LSD, and psilocybin as some of the least harmful drugs.

Authors

  • Robin Carhart-Harris
  • David Nutt

Published

Journal of Psychoactive Drugs
individual Study

Abstract

A web-based survey was used to consult the opinions of experienced drug users on matters related to drug harms. We identified a rare sample of 93 drug users with personal experience with 11 different illicit drugs that are widely used in the UK. Asked to assess the relative harms of these drugs, they ranked alcohol and tobacco as the most harmful, and three “Class A” drugs (MDMA, LSD, and psilocybin) and one class B (cannabis) were ranked as the four least harmful drugs. When asked to assess the relative potential for benefit of the 11 drugs, MDMA, LSD, psilocybin, and cannabis were ranked in the top four; and when asked why these drugs are beneficial, rather than simply report hedonic properties, they referred to potential therapeutic applications (e.g., as tools to assist psychotherapy). These results provide a useful insight into the opinions of experienced drug users on a subject about which they have a rare and intimate knowledge.

Available with Blossom Pro

Research Summary of 'Experienced drug users assess the relative harms and benefits of drugs: a web-based survey'

Introduction

Earlier expert-led efforts to rank the harms of drugs have used Delphic or multicriteria approaches and found poor correspondence between expert assessments and existing legal classifications. Those studies typically engaged psychiatrists and other drug experts and produced a harm matrix that weighted physical harm, dependence, and social harm, but they did not directly consult experienced drug users despite users having intimate knowledge of drug effects and harms. Lester and colleagues set out to fill that gap by collecting the opinions of highly experienced drug users about the relative harms and benefits of a range of commonly used illicit substances, together with views on how each substance should be classified under the UK Misuse of Drugs Act and which information sources most influence perceptions of harm. The study therefore aims to compare user-derived rankings with prior expert assessments and to capture qualitative reasons why particular drugs are seen as harmful or beneficial.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

References (1)

Papers cited by this study that are also in Blossom

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Cited By (12)

Papers in Blossom that reference this study

Psychedelics and psychological strengths

Brasher, T., Rosen, D., Spinella, M. · International Journal of Wellbeing (2023)

Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms

Kopra, E., Ferris, J. A., Winstock, A. R. et al. · Journal of Psychopharmacology (2022)

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)

Psychiatry & the psychedelic drugs. Past, present & future

Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)

Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression

Stroud, J., Freeman, T. P., Leech, R. et al. · Psychopharmacology (2017)

88 cited
The relationships of classic psychedelic use with criminal behavior in the United States adult population

Hendricks, P. S., Crawford, M. S., Cropsey, K. L. et al. · Journal of Psychopharmacology (2017)

Serotonin and brain function: a tale of two receptors

Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)

The therapeutic potential of psychedelic drugs: past, present, and future

Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)

Show all 12 papers
Clinical Applications of Hallucinogens: A Review

Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)

174 cited
Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics

Tófoli, L. F., De Araujo, D. B. · International Review of Neurobiology (2016)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

Experienced drug users assess the relative harms... — Research Summary & Context | Blossom